Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | SAT1 | P21673 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8275755 | 1.00 | CARM1 (0.38) | CARM1PRMT6PRMT1PRMT8SAT1 | |
| SCHEMBL16727917 | 1.00 | CARM1 (0.38) | CARM1PRMT6PRMT1PRMT8SAT1 | |
| SCHEMBL19261996 | 0.91 | SIGMAR1 (0.36) | CARM1PRMT6PRMT1PRMT8L3MBTL1 | |
| SCHEMBL21099458 | 0.89 | SIGMAR1 (0.44) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL13165399 | 0.88 | SAT1 (0.39) | SAT1L3MBTL1SIGMAR1TDP1 | |
| SCHEMBL273581 | 0.88 | — | — | |
| SCHEMBL6019205 | 0.88 | SAT1 (0.39) | SAT1L3MBTL1SIGMAR1TDP1 | |
| Hydrochloric Acid SCHEMBL1165197 | 0.85 | — | — | |
| SCHEMBL22704489 | 0.84 | SIGMAR1 (0.43) | CARM1PRMT6PRMT1PRMT8L3MBTL1 | |
| SCHEMBL18359140 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389751-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| EP-3971176-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | Hinova Pharmaceuticals Inc. (CN) | 2022-03-23 | — | — | EP | disclosed |
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021106947-A1 | NOVEL QUINONE DERIVATIVE AND ANTITRYPANOSOMAL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 国立大学法人群馬大学 | 2021-06-03 | — | — | WO | disclosed |
| WO-2020233512-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | 成都海创药业有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| EP-3319960-B1 | PYRIMIDINE DERIVATIVES AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020151738-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-30 | — | — | WO | disclosed |
| US-RE46630-E1 | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHELHEIM INTERNATIONAL GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-9738760-B2 | Aliphatic polycarbonate compositions and methods | NOVOMER, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170160252-A1 | CHEMICAL SELF-DOPING OF ONE-DIMENSIONAL ORGANIC NANOMATERIALS FOR HIGH CONDUCTIVITY APPLICATION IN CHEMIRSISTIVE SENSING GAS OR VAPOR | UNIVERSITY OF UTAH | 2017-06-08 | — | — | US | disclosed |
| EP-3042898-A1 | PHOTOCHROMIC MATERIALS THAT INCLUDE 6-AMINO SUBSTITUTED INDENO-FUSED NAPHTHOPYRANS | TRANSITIONS OPTICAL, INC. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TCOF1, SLC10A2, PAM | CARM1 1330/4885PRMT6 2148/4885PRMT1 2160/4885 |
| US-20170160252-A1 | CHEMICAL SELF-DOPING OF ONE-DIMENSIONAL ORGANIC NANOMATERIALS FOR HIGH CONDUCTIVITY APPLICATION IN CHEMIRSISTIVE SENSING GAS OR VAPOR | DRD1, DRD4, DNER | CARM1 456/4885PRMT6 311/4885PRMT1 52/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | CARM1 1010/4885PRMT6 805/4885PRMT1 455/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | CARM1 4242/4885PRMT6 2858/4885PRMT1 2896/4885 |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | CARM1 1267/4885PRMT6 2313/4885PRMT1 1922/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CARM1 824/4885PRMT6 1616/4885PRMT1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.